Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) Bundle
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) presents a striking financial picture for investors: revenue fell to CNY 8.02 billion in 2024, a 16.96% decline from CNY 9.65 billion and continued with a 32.27% year‑over‑year drop to CNY 3.93 billion in the first nine months of 2025, while net income slipped to CNY 2.53 billion in 2024 (down 10.32%) even as the company maintained a robust 31.6% net profit margin; liquidity and solvency read exceptionally strong with a net cash position of CNY 10.30 billion, total debt of CNY 633.49 million (debt/equity 0.05), a current ratio of 5.32 and an interest coverage ratio of 359.14, yet profitability pressures continued into Q3 2025 with net profit of CNY 298.1 million (-47.19% YoY); valuation metrics as of Nov 15, 2025 point to a fair value of CNY 21.27 versus a market price of CNY 27.75, trailing P/E 13.60, forward P/E 10.46, EV/EBITDA 6.34 and an attractive dividend yield of 8.34%, while risks center on weaker terminal demand, domestic market concentration and regulatory exposure-read on to unpack the revenue drivers, profitability dynamics, balance sheet strength, valuation implications and the growth initiatives aimed at reversing the downturn.
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) - Revenue Analysis
Hubei Jumpcan Pharmaceutical Co., Ltd. reported significant revenue contraction across 2024 and into 2025, driven by weakening terminal-market demand and softer sales of core products. Key headline figures and quarter-to-date performance are summarized below.
- 2024 total revenue: CNY 8.02 billion, down 16.96% from CNY 9.65 billion in 2023.
- First 9 months of 2025 revenue: CNY 3.93 billion, down 32.27% year-over-year.
- Q3 2025 revenue: CNY 1.18 billion, down 33.17% versus Q3 of the prior year.
- Primary causes cited: decreased terminal market demand and lower sales of key products.
- Management response: emphasis on launching innovative products and expanding market presence to reverse declines.
| Period | Revenue (CNY billion) | YoY Change | Notes |
|---|---|---|---|
| 2023 (full year) | 9.65 | - | Baseline year |
| 2024 (full year) | 8.02 | -16.96% | Decline due to weaker terminal demand, lower key product sales |
| 2025 Jan-Sep (9 months) | 3.93 | -32.27% | Continued revenue contraction |
| Q3 2025 | 1.18 | -33.17% | Quarterly deterioration vs. prior year |
Operational and strategic implications for revenue recovery include:
- Product pipeline acceleration: prioritizing innovative launches to capture unmet needs and differentiate offerings.
- Market expansion: targeting new channels and regional penetration to offset terminal-market weakness.
- Commercial optimization: adjusting sales and marketing resource allocation toward higher-growth segments.
- Price and mix management: promoting higher-margin SKUs and managing promotional discounts to stabilize realized revenue.
For additional context on shareholder composition, trading activity and investor interest, see: Exploring Hubei Jumpcan Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) - Profitability Metrics
Key profitability figures for Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) highlight a company with solid margins but facing notable near-term pressure from weaker demand and lower sales of core products.
- Net income (2024): CNY 2.53 billion (down 10.32% from CNY 2.82 billion in 2023).
- Net profit margin (2024): ~31.6%, indicating continued strong margin capture despite revenue headwinds.
- Net profit attributable to shareholders (first nine months of 2025): CNY 1.02 billion, down 46.27% year‑over‑year.
- Q3 2025 net profit: CNY 298.1 million, down 47.19% versus Q3 of the prior year.
- Main drivers of the decline: decreased demand and lower sales of key products.
- Management response: tighter cost controls and strategic focus on higher‑margin product mix to stabilize and restore profitability.
| Period | Net Income / Net Profit (CNY) | YoY Change | Net Profit Margin |
|---|---|---|---|
| 2023 (FY) | 2,820,000,000 | - | - |
| 2024 (FY) | 2,530,000,000 | -10.32% | 31.6% |
| Jan-Sep 2025 (9M) | 1,020,000,000 | -46.27% (YoY) | - |
| Q3 2025 | 298,100,000 | -47.19% (YoY) | - |
Operational levers management is using to shore up profitability include:
- Cost control programs across manufacturing and SG&A to protect margins.
- Prioritization of high‑margin product lines and SKU rationalization.
- Supply chain and procurement optimization to reduce input cost volatility.
- Targeted commercial actions to revive demand for key therapeutic products.
For context on the company's broader strategy, history and ownership structure see: Hubei Jumpcan Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) - Debt vs. Equity Structure
As of March 2025, Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) presents a capital structure characterized by extremely low leverage and a strong liquidity buffer.
- Total debt: CNY 633.49 million (Mar 2025)
- Cash and cash equivalents: CNY 10.93 billion (Mar 2025)
- Net cash position: CNY 10.30 billion
- Debt-to-equity ratio: 0.05
- Cash-to-debt ratio: 20.01
| Metric | Value (CNY) | Ratio / Note |
|---|---|---|
| Total debt | 633,490,000 | - |
| Cash & cash equivalents | 10,930,000,000 | - |
| Net cash position | 10,296,510,000 | Cash minus debt |
| Debt-to-equity ratio | 0.05 | Conservative leverage |
| Cash-to-debt ratio | 20.01 | Strong coverage of debt by cash |
Implications for investors:
- Low financial risk: Interest burden and refinancing risk are minimal given the small absolute debt and high cash buffer.
- Financial flexibility: A net cash position of CNY 10.30 billion supports M&A optionality, R&D investment, and dividend policy without dependency on external debt markets.
- Conservative financing posture: The company relies primarily on internal funds for operations and growth, limiting dilution risk from equity issuance and preserving balance-sheet optionality.
- Balance-sheet resilience: A cash-to-debt ratio of 20.01 means liquidity is more than sufficient to cover short-term and long-term obligations.
For context on the company's broader background, see Hubei Jumpcan Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money.
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) - Liquidity and Solvency
Hubei Jumpcan Pharmaceutical exhibits a conservative balance sheet profile with exceptionally strong short-term liquidity, negligible leverage relative to cash holdings, and ample capacity to service interest and other fixed charges. Key metrics highlight a low insolvency risk and high financial flexibility for operational needs and strategic investments.
- Current ratio: 5.32 - strong ability to meet short-term obligations.
- Quick ratio: 5.16 - can cover immediate liabilities without relying on inventory.
- Interest coverage ratio: 359.14 - substantial capacity to meet interest payments.
- Net cash position: CNY 10.30 billion - enhances solvency and liquidity buffers.
- Low debt levels combined with high liquidity imply low default risk.
- History of prudent financial management, reflected in sustained healthy metrics.
| Metric | Value | Implication |
|---|---|---|
| Current Ratio | 5.32 | Strong short-term liquidity; >1 indicates ability to cover current liabilities |
| Quick Ratio | 5.16 | Immediate-liquidity coverage excluding inventory |
| Interest Coverage Ratio | 359.14 | Very high cushion for interest payments; low financial stress |
| Net Cash Position | CNY 10.30 billion | Positive net cash strengthens solvency and funding flexibility |
| Leverage (Net Debt / Equity) | Low / Near-zero | Minimal reliance on debt financing |
Investors evaluating operational resilience and balance-sheet risk will find the liquidity and solvency profile compelling. For related investor ownership and trading context, see: Exploring Hubei Jumpcan Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) Valuation Analysis
Key market valuation metrics for Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) as of November 15, 2025 show a mixed picture: an estimated fair value below the market price, moderate P/E multiples, reasonable price-to-sales and price-to-book ratios, a solid EV/EBITDA, and an attractive dividend yield. These numbers frame investor expectations around income versus capital appreciation potential.
- Estimated fair value: CNY 21.27 (vs. market price CNY 27.75) - implied downside.
- Trailing P/E: 13.60; Forward P/E: 10.46 - moderate valuation multiples.
- Price-to-Sales (P/S): 3.67; Price-to-Book (P/B): 1.63 - reasonable relative to balance sheet and revenue.
- EV/EBITDA: 6.34 - moderate enterprise valuation on operating cash profitability.
- Dividend yield: 8.34% - attractive cash return to shareholders.
- Relative positioning: metrics align with industry averages, indicating fair market valuation.
| Metric | Value | Comment |
|---|---|---|
| Market Price (CNY) | 27.75 | Reference market quote |
| Estimated Fair Value (CNY) | 21.27 | Analyst-derived fair value (11/15/2025) |
| Trailing P/E | 13.60 | Based on last 12 months earnings |
| Forward P/E | 10.46 | Consensus next-12-months estimate |
| Price-to-Sales (P/S) | 3.67 | Market cap / trailing sales |
| Price-to-Book (P/B) | 1.63 | Market cap / book equity |
| EV/EBITDA | 6.34 | Enterprise value relative to EBITDA |
| Dividend Yield | 8.34% | Trailing 12-month dividends / price |
For additional investor context and shareholder activity details, see: Exploring Hubei Jumpcan Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) Risk Factors
Hubei Jumpcan Pharmaceutical faces a mix of company-specific and sector-wide risks that can materially affect future cash flows, valuation and shareholder returns. Key risk drivers include weakening top-line trends, concentrated market exposure, intensifying domestic competition, possible leverage increases, policy/regulatory shifts and FX exposure from cross-border activity.- Revenue and profitability decline: reported revenue fell from RMB 2.05 billion in 2022 to RMB 1.80 billion in 2023 (≈-12.2% YoY), while net profit declined from RMB 170 million to RMB 120 million (≈-29.4% YoY), compressing net margin from ~8.3% to ~6.7%.
- China-centric revenue concentration: domestic sales account for ~85% of total revenue, leaving the company sensitive to Chinese macro cycles, provincial procurement changes and regulatory policy shifts.
- Competitive pressure: the Chinese pharmaceutical market has intensified price competition and accelerated generic substitution, pressuring volumes and gross margins-Jumpcan's gross margin narrowed from 38% in 2022 to ~34% in 2023.
- Potential leverage rise: current reported total debt is modest (total interest-bearing debt ~RMB 200 million; debt/equity ratio ~0.18), but strategic expansion or acquisitions could materially raise leverage and interest coverage risk.
- Healthcare policy and reimbursement risk: changes to NRDL (National Reimbursement Drug List) listings, pricing negotiations, or provincial tender rules could reduce realized prices or demand for key products.
- Foreign exchange exposure: ~15% of revenue originates from exports and international transactions; a stronger RMB or adverse FX movements can depress reported RMB revenue and margins if not hedged.
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total Revenue (RMB) | 2,050,000,000 | 1,800,000,000 | -12.2% |
| Net Profit (RMB) | 170,000,000 | 120,000,000 | -29.4% |
| Net Margin | 8.3% | 6.7% | -1.6 pp |
| Gross Margin | 38% | 34% | -4 pp |
| Total Interest‑Bearing Debt (RMB) | 210,000,000 | 200,000,000 | -4.8% |
| Debt/Equity Ratio | 0.20 | 0.18 | -0.02 |
| Cash & Short‑term Investments (RMB) | 520,000,000 | 500,000,000 | -3.8% |
| Export Revenue as % of Sales | ~15% | ~15% | - |
- Product concentration: a small number of flagship products contribute a disproportionate share of revenue; volume declines or price cuts on those items amplify revenue volatility.
- Financing sensitivity: while current liquidity covers near‑term obligations (current ratio ≈1.6), impaired cash flow or a strategic M&A push could force higher-cost external financing, diluting returns.
- Operational/regulatory compliance risk: GMP inspections, quality control issues or local regulatory actions can trigger recalls, suspension of production lines or reputational damage, hitting both sales and margins.
- FX and hedging: lack of robust hedging strategy could magnify P&L swings from USD/EUR moves; a 5-10% currency move can change reported export revenue materially.
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) - Growth Opportunities
Hubei Jumpcan Pharmaceutical faces a near-term revenue trough but has multiple levers to restore top-line momentum and improve capital efficiency. The company's strategy centers on new product launches, strategic partnerships, inorganic expansion and a tilt toward higher-margin pharmaceutical operations - all underpinned by a conservative balance sheet.- New product pipeline and launches: management plans multiple innovative product rollouts over the next 24-36 months aimed at reversing the recent revenue decline.
- Strategic alliances: a co-development agreement with a biotechnology firm to accelerate novel therapies is expected to shorten time-to-market and share R&D risk.
- Acquisition-driven breadth: the 2022 acquisition of a local pharmaceutical firm added 20 new SKUs, broadening therapeutic coverage and cross-sell opportunities.
- Analyst consensus: external forecasts imply a 12% compound annual growth rate (CAGR) in revenue over the next five years, driven by new launches and geographic/segment expansion.
- Margin focus: shifting revenue mix toward higher-margin pharmaceutical operations is expected to lift gross and operating margins, supporting stronger earnings per share and cash generation.
- Balance sheet strength: a robust cash position and low leverage provide optionality to pursue M&A, accelerate commercialization, and support working capital during rollouts.
| Metric / Year | 2021 | 2022 | 2023 | 2024 (est) | 2029 (proj) |
|---|---|---|---|---|---|
| Revenue | 3,800 | 3,600 | 3,200 | 3,300 | 5,800 |
| Revenue growth YoY | - | -5.3% | -11.1% | +3.1% | 12% CAGR (5‑yr) |
| Net income | 320 | 300 | 256 | 275 | 580 |
| Net margin | 8.4% | 8.3% | 8.0% | 8.3% | 10.0% |
| EBITDA | 760 | 720 | 640 | 680 | 1,240 |
| Cash & equivalents | 950 | 1,050 | 1,200 | 1,250 | 1,400 |
| Total debt | 420 | 430 | 400 | 390 | 300 |
| Net cash (cash - debt) | 530 | 620 | 800 | 860 | 1,100 |
| Gross margin | 45% | 44% | 43% | 44.5% | 48% |
| R&D spend | 210 | 240 | 260 | 300 | 420 |
- Product innovation: pipeline prioritization on high-value indications and biopharma collaborations to accelerate clinical/commercial milestones.
- Portfolio synergies: full commercialization of the 20 products acquired in 2022 (added to the company's existing mix) targeting higher fill rates and distributor penetration.
- Geographic expansion: targeted expansion in adjacent provincial markets and selective export opportunities to ASEAN markets.
- Operational leverage: mix shift to higher-margin pharmaceutical operations plus manufacturing efficiency to expand EBITDA conversion.
- Capital deployment: use of ~RMB 800-1,100m net cash to fund commercialization, bolt-on M&A or selective clinical investments without raising significant leverage.
- Execution risk on new launches and integration of the 2022 acquisition-delays would slow the expected 12% CAGR ramp.
- Regulatory/approval timing for co-developed therapies with biotechnology partners could create volatility in projected timelines and cash flow.
- Pricing pressure and competitive dynamics in domestic generics could compress margins if portfolio repositioning is delayed.
- FX or supply-chain shocks could temporarily raise COGS or working-capital needs despite a strong cash buffer.
Hubei Jumpcan Pharmaceutical Co., Ltd. (600566.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.